Celltrion announced on the 16th that the results of a global phase 3 clinical trial, confirming the efficacy and safety of the biosimilar 'Avtozma (AVTOZMA, development name CT-P47),' were published in the international journal Clinical Drug Investigation. Avtozma is a biosimilar of the rheumatoid arthritis (RA) treatment 'Actemra (ACTEMRA, ingredient: tocilizumab).' In the phase 3 clinical trial conducted on 471 rheumatoid arthritis patients, the primary indicators, including efficacy, pharmacokinetics, safety, and immunogenicity, were similar across three groups: the group that continuously received CT-P47, the group that maintained the original drug, and the group that switched to CT-P47.
AstraZeneca Korea announced on the 16th that it has signed a business agreement with Avis for the establishment of an artificial intelligence (AI)-based human epithelial growth factor receptor 2 (HER2) diagnostic ecosystem. Avis is an AI digital pathology solution startup. HER2 is a protein that influences the growth and division of cancer cells. Under the agreement, AstraZeneca Korea will introduce Avis's AI-based biomarker quantification solution 'Quanty IHC' HER2 diagnostic technology into domestic clinical settings. A joint research project will also be pursued to verify the clinical usability of the AI-based HER2 diagnostic technology.
Hanmi Pharmaceutical announced on the 16th that it had signed a business agreement for the joint development and utilization of a 'fact sheet based on domestic eye disease statistics' at its headquarters in Songpa-gu, Seoul, on the 9th. This agreement aims to collect and analyze quantitative data on major eye diseases, such as refractive errors, low vision, and presbyopia, to produce an 'eye disease fact sheet' that can be directly utilized in ophthalmology clinics. The two companies plan to carry out various joint projects, including research into big data related to eye diseases among Koreans, examining the prevalence of specific ophthalmic diseases and estimating populations, analyzing eye examination patterns, and producing and distributing fact sheets to support ophthalmic care. In this process, Hanmi Pharmaceutical will be responsible for statistical analysis and visualization related to eye diseases.
Neurophet announced that it conducted a subscription offering for general investors on the 15th and 16th, recording a subscription competition rate of 1,922.75 to 1. A total of 279,248 subscriptions were received, with about 6.73 trillion won in pre-paid deposits accounting for half of the subscription amount. In a demand forecast conducted from July 4 to 10, 2,444 domestic and foreign institutional investors participated, achieving a competition rate of 1,087.6 to 1, finalizing the public offering price at 14,000 won.
GC Biopharma announced on the 16th that it has conducted a social contribution activity 'Sound Dream,' where employees donated their voices. They donated recordings of themselves reading fairy tales to multicultural families and visually impaired children. The recordings will be delivered to the Yongin Family Center along with 60 fairy tale books, contained in five recording devices.
Huons Global announced on the 16th that it has donated 10 million won to the non-profit organization 'Now for Our Painful Colleagues.' The donation will be used for police officers enduring extreme situations, supporting their post-traumatic stress disorder (PTSD) and psychological treatment.
Soldoc announced on the 16th that it has been selected for the '2025 Scale-up TIPS' project organized by the Ministry of SMEs and Startups. The company will develop a next-generation telemedicine artificial intelligence (AI) platform that links everything from data collection to diagnosis and treatment. The project provides up to 1.2 billion won in research and development funding for companies that receive over 1 billion won in investments from private operators for three years. If follow-up investments are secured, additional equity investments of up to 2 billion won will be made.
Ildong Pharmaceutical Group's subsidiary Ildong Living Health announced on the 16th that it has launched the 'First Lab Probiotic Moisture Sun Serum' from its functional cosmetics brand First Lab. It helps with UV protection, skin whitening, and wrinkle improvement, containing fermented materials from lactic acid bacteria, 98% pure glutathione, and eight types of hyaluronic acid.
CHA Biotech announced on the 16th that it has been selected as the recipient of the 'G-Rex Grant Program' and has received a subsidy of $150,000 (2 billion won). G-Rex is a system optimized for large-scale immune cell culture. It efficiently supplies oxygen and nutrients through a gas-permeable membrane, promoting cell growth. Global biotech companies such as ScaleReady, Wilson Wolf, and Celularity are running programs that provide subsidies of $20 million (27.7 billion won) for the development of cell and gene therapies.
Hallym University Medical Center announced on the 16th that it has developed a generative AI platform called 'HAI.' HAI drafts electronic medical records from admission to discharge. It applies to five clinical departments: stroke, cholecystitis, cesarean delivery, lens surgery, and tonsil and adenoid surgeries. It can provide patients with quick and accurate services.